4. Risk of bias summary for trials in the included reviews.
Review | N trials | randomisation % | Sustained abstinence % | Biochemical validation % |
Blinding % |
||
Low risk | Unclear risk |
High risk |
Low risk | ||||
NRT | 147 | 25 | 72 | 3 | 70 | 86 | 33 |
Antidepressants | 60 | 48 | 50 | 2 | 85 | 85 | 50 |
Nic recep partial ags | 24 | 66 | 33 | ‐ | 75 | 84 | 58 |
Anxiolytics | 7 | ‐ | 100 | ‐ | 29 | 29 | 0 |
Clonidine | 6 | ‐ | 100 | ‐ | 0 | 67 | 0 |
Lobeline | 0 | No included studies | |||||
Mecamylamine | 2 | 100 | ‐ | ‐ | 100 | 100 | 100 |
Nicobrevin | 0 | No included studies | |||||
Nicotine vaccines | 4 | 25 | 75 | ‐ | 50 | 50 | 50 |
Opioid antagonists | 4 | 50 | 50 | ‐ | 50 | 100 | 100 |
Rimonabant | 3 | ‐ | 100 | ‐ | 100 | 100 | 0 |
Silver acetate | 2 | ‐ | 100 | ‐ | 100 | 100 | 50 |
Numbers from columns 3 to 8 are percentages of the total number of trials for each review.